Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ActiGel is a bio-active vaginal gel used for the treatment and prevention of bacterial vaginosis (BV) and related vaginal discomforts such as discharge, odor, itching, and irritation. Developed by BioClin (now part of Karo Healthcare) and distributed by GyneBio Pharma in specific regions, the product's efficacy is based on the patented 2QR-complex. The 2QR-complex is a polysaccharide mixture derived from the leaf juice of *Aloe barbadensis* that functions through a physical mechanism of action. It binds to the adhesins on the surface of pathogenic bacteria, effectively neutralizing them and preventing their attachment to the vaginal mucosa. This process helps restore the natural balance of the vaginal flora by favoring the growth of beneficial lactobacilli without the use of traditional antibiotics.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ActiGel.